TY - JOUR
T1 - Nonalcoholic Fatty Liver Disease
T2 - Identification and Management of High-Risk Patients
AU - Cheung, Amanda
AU - Figueredo, Carlos
AU - Rinella, Mary Eugenia
N1 - Publisher Copyright:
© 2019 by The American College of Gastroenterology.
PY - 2019/4/1
Y1 - 2019/4/1
N2 - Nonalcoholic fatty liver disease (NAFLD) is an increasingly dominant cause of liver disease worldwide. The progressive subtype, nonalcoholic steatohepatitis, is a leading indication for liver transplantation and a noteworthy cause of hepatocellular carcinoma. The overall prevalence of NAFLD is on the rise, and even more concerning data modeling predicts that an increasing percentage of those with NAFLD will develop advanced disease. This increased volume of patients with advanced liver disease will impose a significant health care burden in terms of resources and cost. Thus, the identification of patients with established fibrosis or at high risk of developing advanced liver disease is critical to effectively intervene and prevent overall and liver-related morbidity and mortality. Herein, we provide a framework to consider for the identification of patients with NAFLD at high risk of nonalcoholic steatohepatitis with advanced fibrosis and provide a critical assessment of currently accessible diagnostic and treatment modalities.
AB - Nonalcoholic fatty liver disease (NAFLD) is an increasingly dominant cause of liver disease worldwide. The progressive subtype, nonalcoholic steatohepatitis, is a leading indication for liver transplantation and a noteworthy cause of hepatocellular carcinoma. The overall prevalence of NAFLD is on the rise, and even more concerning data modeling predicts that an increasing percentage of those with NAFLD will develop advanced disease. This increased volume of patients with advanced liver disease will impose a significant health care burden in terms of resources and cost. Thus, the identification of patients with established fibrosis or at high risk of developing advanced liver disease is critical to effectively intervene and prevent overall and liver-related morbidity and mortality. Herein, we provide a framework to consider for the identification of patients with NAFLD at high risk of nonalcoholic steatohepatitis with advanced fibrosis and provide a critical assessment of currently accessible diagnostic and treatment modalities.
UR - http://www.scopus.com/inward/record.url?scp=85064320510&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85064320510&partnerID=8YFLogxK
U2 - 10.14309/ajg.0000000000000058
DO - 10.14309/ajg.0000000000000058
M3 - Review article
C2 - 30839326
AN - SCOPUS:85064320510
SN - 0002-9270
VL - 114
SP - 579
EP - 590
JO - American Journal of Gastroenterology
JF - American Journal of Gastroenterology
IS - 4
ER -